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.2011.12.Abstract Objective: Sinonasal surgery is one of the shared airway surgeries that are not uncom-
monly complicated intra or postoperatively. The proper anesthetic management of these cases plays
a crucial role creating a bloodless ﬁeld. Sugammadex is a new selective relaxant binding drug as it
provides a rapid decrease in free rocuronium in the plasma and at nicotinic receptor that help
proper awakening of these patients which is extremely important for minimizing the postoperative
respiratory complications. The aim of this study is to compare recovery proﬁle in sinonasal surgery
in patients reversed by conventional anticholine esterase (Neostigmine) versus those reversed by
Sugammadex.
Methods: This study included 40 patients ASA physical status I and II aged 20–45 years with
chronic sinusitis undergoing endoscopic sinus surgery with or without septoplasty, hypotensive
anesthesia to maintain MAP (50–60 mm Hg), muscle relaxation throughout the procedure at 1–2
posttetanic count (PTCs) by rocuronium infusion, and anesthetic depth maintained using BIS
(50–60). Patients were allocated randomly into two equal groups to receive either Sugammadex
4 mg/kg (group I) or Neostigmine 0.05 mg/kg and atropine 0.02 mg/kg (group II) as a reversal
agent, and assessment of postoperative respiratory complications was performed using the Postop-
erative Respiratory System Evaluation Score (PRSES) at 1st and 5th minutes after extubation.
Results: The reversal time showed highly signiﬁcant difference between the two groups. Patients in
the Sugammadex group could reach a TOF of 0.9 in a mean time 2.47 (0.51) min versus 24.21
(4.7) min for the Neostigmine group; postoperative respiratory complications, the Sugammadex
group and the Neostigmine group did not differ statistically; however, more patients in Neostigminem (E.A. Fouad Ali).
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176 N. Mekawy, E.A. Fouad Aligroup showed respiratory complications at 1st and 5th minutes after extubation as shown by
PRSES Scoring System.
Conclusion: This study showed that the use of Sugammadex in reversing rocuronium induced neu-
romuscular block in patients undergoing functional endoscopic surgery is superior to Neostigmine.
Further studies are required to weigh the cost beneﬁt relationship of the use of Sugammadex in rou-
tine clinical practice.
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Sinonasal surgery is one of the shared airway surgeries that are
not uncommonly complicated intra or postoperatively due to
factors related either to the surgeon or to the type of surgery
itself [1]. The spread of endoscopic sinus surgery is aiming
for minimizing surgical invasiveness, blood loss, and pain than
the open method for all mild and moderate cases [2].
The proper anesthetic management of these cases plays a
crucial role to minimize the intra-operative conditions by cre-
ating a bloodless ﬁeld by using peripheral vasodilator, beta
blockers, and ensuring deep muscle relaxation, thus facilitating
the endoscopic surgical intervention [3,4].
As for postoperatively, proper awakening of these patients
is extremely important for minimizing the postoperative respi-
ratory complications as laryngo-spasm, stridor, and difﬁculty
in breathing, so that adequate reversal of the residual of
non-depolarizing neuromuscular blocking drugs at the end of
the surgery is of critical importance for avoiding these compli-
cations in the early postoperative period [5], as it involves the
muscles that maintain the patency of the airway or attenuate
the ventilatory response to hypoxia especially with the patients
who had postoperative nasal obstructions [6].
Sugammadex is a new selective relaxant binding drug that is
designed to encapsulate steroidal non-depolarizing neuromus-
cular blocking agents (NDBAs) and that will allow an effective
reverse of any degree of block of both rocuronium and vecuro-
nium [7], as it provides a rapid decrease in free rocuronium in
the plasma and subsequently at nicotinic receptor at motor end
plate; this promotes the liberation of acetylcholine in which its
deﬁciency may prolong the action of neuromuscular blocking
agent [8]. It is a modiﬁed –c– cyclodextrin compound (Orga-
non USA Inc., Roseland NJ). Therefore, its mechanism of ac-
tion does not result in stimulation of the cholinergic nervous-
system [9], thereby avoiding undesirable side effects of rou-
tinely used anticholinesterases that need addition of musca-
rinic antagonist [10].
Aim of the study: Is to compare recovery proﬁle in sinonasal
surgery in patients reversed by conventional anticholine ester-
ase (Neostigmine) versus those reversed by Sugammadex.
2. Methods
The study was performed in Kasr el- Ainy hospital in ENT
department, 40 patients ASA physical status I and II aged
20–45 years with chronic sinusitis undergoing endoscopic sinus
surgery with or without septoplasty were included in the study.
Patients enrolled in the study were allocated randomly into two
equal group – using a computer generated system – to receive
either Sugammadex 4 mg/kg (group I) or Neostigmine 0.05
mg/kg and atropine 0.02 mg/kg (group II) as a reversal agent.The study excluded patients with cardiovascular system
pathology, coagulation defects, bronchial asthma, COPD, or
who have muscle disease or neuromuscular disorder. Patients
with renal, hepatic diseases and those who are taking any
drugs that affect renal function or blood coagulation were also
excluded from the study. Patients with history of difﬁcult intu-
bation or suspected to be difﬁcult were also excluded from the
study.
Premedication was omitted in all patients. Upon arrival to
the operating room, monitors were applied for heart rate read-
ing, mean arterial blood pressure (non-invasively), and pulse
oximeter for O2 saturation values. Also, the silver chloride
electrodes of nerve stimulator were applied over the ulner
nerve, and neuromuscular data were monitored using accelr-
omyography (TOF guard, shering plough-Ireland).
Standard BIS monitor strip (BIS X, Aspect medical system,
Norwood, MA, USA) was placed on the patient forehead of
the dominant hemisphere according to the guidelines of the
manufacturer.
A 20 gauge venous cannula was inserted on the dorsum of
the hand. Preoxygenation with 100% oxygen was performed
for 5 min while asking the patient to perform mouth breathing
during this time calibration of the TOF guard was performed.
Induction of anesthesia with propofol 2–2.5 mg/kg, fentanyl
1 lq/kg, and then rocuronium 0.6 mg/kg was administered to
facilitate tracheal intubation and was performed when com-
plete blockade occurs as shown by the TOF guard. Ventilator
was controlled to maintain end tidal CO2 at 30–35 mm Hg.
Another IV cannula 20 gauge that was introduced for
hypotensive agent infusion Nitroglycerine at a dose of 0.5–
5 lq/kg/min was used and titrated to maintained mean arterial
pressure between 50 and 60 mm Hg, and propranolol (B-
blocker) was given at dose 0.01–0.015 mg/kg to maintain HR
and controlling tachycardic reﬂex of Nitroglycerine. Muscle
relaxant infusion at 10–15 lq/kg/min was used to maintain
muscle relaxation throughout the procedure at 1–2 posttetanic
count (PTCs). Anesthesia was maintained with 50% oxygen in
air and 1.5 MAC isoﬂurane; before patient positioning, an
oro-pharyngeal pack was introduced; and then, the patient
positioned with head up 30 before surgery started. By the
end of the surgical procedure, the surgeon introduced a nasal
pack. We stopped the relaxant infusion, the hypotensive
agents, and isoﬂurane was minimized to 0.4%, and the naso-
pharyngeal pack was then removed followed by proper inspec-
tion for postnasal bleeding and through suctioning.
Upon the appearance of the T2, discontinuation of isoﬂu-
rane was performed, and either Sugammadex 4 mg/kg or Neo-
stigmine 0.05 mg/kg and atropine 0.02 mg/kg were given to the
patients (both prepared in identical 10 ml syringe) by a resident
who was blind to the drug injected. Adequate return of neuro-
muscular function was assessed by the TOF guard. Extubation
Table 1 Postoperative Respiratory System Evaluation Scoring (PRSES) [11].
PRSES-1 Normal respiratory pattern, respiratory rate <16 and deep enough
PRSES-2 Cough reﬂex, at least three times without pause times/minute (with retching sound, strain, or short duration of apnea)
PRSES-3 Spasmodic respiratory pattern, extension of exprium
PRSES-4 Partial laryngospasm, severe inspiratory stridor (which can be treated by positive ventilation with oxygen)
PRSES-5 Complete laryngospasm, no air exchange (which needs muscle relaxation with succinylcholine for ventilation)
Table 4 Incidence of postoperative respiratory complication
using (PRSES score) in both groups [number (%)].
Sugammadex
group (n= 20)
Neostigmine
group (n= 20)
P value
1 min
Press 1 13 (65%) 10 (50%) 0.50
Press 2 6 (30%) 8 (40%) 0.74
Press 3–5 1 (5%) 2 (10%) 0.99
5 min
Press 1 16 (80%) 12 (35%) 0.30
Press 2 4 (20%) 7 (35%) 0.48
Press 3–5 0 (0%) 1 (5%) 0.99
Improved recovery proﬁles in sinonasal surgery Sugammadex 177was performed at TOF ratio of 0.9 and after performing clin-
ical signs of recovery and after full awakening and ability of
the patient to follow verbal commands. The time from admin-
istration of the study drug till TOF ratio of 0.9 is considered
the reversal time immediately after extubation all patients were
asked to perform 5 s head lift and hand squeeze for 5 s.
A scoring system of postoperative respiratory complication
was performed using the Postoperative Respiratory System
Evaluation Score (PRSES) at 1st and 5th minutes after extuba-
tion [11] Table 1.
3. Statistical analysis
Data were presented as mean (SD) or number (%) as appropri-
ate. Comparison between the two groups was performed using
unpaired Student’s t test. Categorical variable were compared
using Chi-squared or Fisher’s exact tests as appropriate. A p
value less than 0.05 was considered statistically signiﬁcant.
4. Results
A total of 54 patients consented to participate in this study,
and all were ASA I and II. Nine patients were excluded be-
cause they did not meet the inclusion criteria, and ﬁve patients
were withdrawn from the study due to inability to apply the
study protocol; these ﬁve patients had BIS reading higher than
60 before the reversal drug injection that mandates reopening
of inhalational agents which violates the study protocol.
There was no signiﬁcant demographic difference among the
two groups (Table 2). The duration of surgery, isoﬂurane con-
sumption, Nitroglycerine requirements, rocuronium supple-Table 2 Demographic data of both groups [mean (SD) or
ratio].
Group I (n= 20) Group II (n= 20) P value
Age (years) 28.2 (5.7) 31.4 (6.8) 0.115
Weight (kg) 74.9 (9.8) 76.8 (11.2) 0.248
Sex (male/female) 17/3 11/9 0.082
ASA (I/II) 14/6 16/4 0.711
Table 3 Intra- and postprocedure data in both groups [mean (SD)
Group I (n= 20)
Duration of the surgery (min) 102.3 (12.4)
Isoﬂurane consumption (ml) 54.3 (11.9)
Nitroglycerine requirement (mg) 11.6 (2.4)
Rocuronium supplemented (mg) 67.2 (8.3)
Intraoperative blood loss (ml) 104.6 (13.2)
Recovery time (min) 2.47 (0.51)mented, and intraoperative blood loss were comparable and
showed no differences between the two groups (Table 3).
As for the reversal time, it showed highly signiﬁcant differ-
ence between the two groups; patients in the Sugammadex
group could reach a TOF of 0.9 in a mean time 2.47
(0.51) min versus 24.21 (4.7) min for the Neostigmine group
Table 3.
As for the clinical signs of recovery, 17 of 20 patients in the
Sugammadex group and 15 of the 20 patients in the Neostig-
mine group were awake and oriented before transfer to the
PACU p= 694.
After extubation, one patient only in the Sugammadex
group and four patients in the Neostigmine group were unable
to perform sustained head left for 5 s p= 0.341.
As for postoperative respiratory complications, the Sug-
ammadex group and the Neostigmine group did not differ sta-
tistically; however, more patients in Neostigmine group
showed respiratory complications at 1st and 5th minutes after
extubation as shown by PRSES Scoring System (Table 4).
5. Discussion
The current study showed that – compared to Neostigmine –
the use of the novel reversal agent Sugammadex to reverse a
steady state of relaxation provided by rocuronium infusion].
Group II (n= 20) P value
106.7 (15.1) 0.32
52.9 (10.7) 0.693
12.3 (1.8) 0.303
70.1 (9.4) 0.307
111.2 (9.8) 0.060
24.21 (4.7) <0.0001
178 N. Mekawy, E.A. Fouad Aliwas associated with more rapid and complete reversal with less
postoperative respiratory complications.
The study also focused on beneﬁts of ensuring a rapid and
complete reversal after a procedure that shares the airway and
mandates proper and full recovery of the airway reﬂexes after
awakening.
The study demonstrated that Sugammadex was associated
with much faster reversal time 2.47 (0.51) min versus 24.21
(4.7) min for Neostigmine resulting in a reversal time, which
is almost 10 time faster than Neostigmine, and this rapid rever-
sal after functional endoscopic surgery is highly desirable since
these patients have obstructed nose with nasal pack and the
prompt and complete return of the airway reﬂexes and neuro-
muscular function will help them to maintain a patent airway.
The recovery to a TOF ratio of 0.9 is considered the stan-
dard for neuromuscular recovery after neuromuscular blockers
[12]. This is the rational behind choosing the time from injec-
tion of the reversal until a TOF of 0.9 as the reversal time in
the current study.
The use of Neostigmine for the reversal of residual neuro-
muscular block is only permitted once recovery has already
started; therefore, the appearance of the second twitch T2 of
the train of four responses should be detected before the injec-
tion of Neostigmine [13].
Therefore, the appearance of T2 was chosen as a prerequi-
site prior to injection of any reversal agents to permit proper
comparison of the study drugs.
The results of the present study were concomitant with
those found in previous studies that compared the reversal
using either Sugammadex or Neostigmine or Edrophonium
[14] and concluded that Sugammadex was way faster in revers-
ing rocuronium and vecuronium induced neuromuscular block
than other reversal agents.
Also, previous studies have shown that Sugammadex at
doses of 4 mg/kg and 8 mg/kg was able to reverse profound
neuromuscular block induced by rocuronium in a mean time
1.7 min [15].
In the current study, the reversal agent was administered as
the volatile agent was discontinued which is the usual clinical
practice in anesthesia to allow the assessment of the reversal
time without being inﬂuenced by the volatile agent, and this
is contradictory to the study of Bradely et al. in which the vol-
atile agent continued until the TOF ratio of reached 0.9 [12].
Many studies have shown that residual neuromuscular
blockade is associated with various complications in the recov-
ery room with subsequent morbidity and mortality [16]. In our
study, none of the patients showed residual neuromuscular
blockade, and all patients were able to reach a TOF of 0.9.
Unlike the study of White et al. [14] which administered the
Sugammadex in the presence of the volatile anesthetic, the cur-
rent study administered the drug while the anesthetic has been
discontinued since volatile anesthetic can potentiate the neuro-
muscular junction and this can potentially slow the reversal pro-
cess. However, to exclude the risk of awareness in the patients of
the current study, the BIS monitor was used and patients were
excluded if the BIS was 60 or more before the reversal agent
injection and reopening of the isoﬂurane was performed.
In conclusion, this study showed that the use of Sugamma-
dex in reversing rocuronium induced neuromuscular block inpatients undergoing functional endoscopic surgery is superior
to Neostigmine. Further studies are required to weigh the cost
beneﬁt relationship of the use of Sugammadex in routine clin-
ical practice.
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